Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

HDAC inhibitors in liver cancer: which route to take?

Kiesslich T, Neureiter D.

Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):515-517. doi: 10.1080/17474124.2019.1605289. Epub 2019 Apr 17. No abstract available.

PMID:
30991854
2.

The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics.

Beyreis M, Gaisberger M, Jakab M, Neureiter D, Helm K, Ritter M, Kiesslich T, Mayr C.

Cancers (Basel). 2019 Feb 26;11(3). pii: E276. doi: 10.3390/cancers11030276.

3.

Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells.

Aghamaliyev U, Gaitantzi H, Thomas M, Simon-Keller K, Gaiser T, Marx A, Yagublu V, Araos J, Cai C, Valous NA, Halama N, Kiesslich T, Ebert M, Grützmann R, Rückert F, Breitkopf-Heinlein K.

Eur Surg Res. 2019 Jan 16;60(1-2):1-12. doi: 10.1159/000494734. [Epub ahead of print]

PMID:
30650425
4.

Glycine Induces Migration of Microglial BV-2 Cells via SNAT-Mediated Cell Swelling.

Kittl M, Dobias H, Beyreis M, Kiesslich T, Mayr C, Gaisberger M, Ritter M, Kerschbaum HH, Jakab M.

Cell Physiol Biochem. 2018;50(4):1460-1473. doi: 10.1159/000494646. Epub 2018 Oct 25.

5.

Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.

Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F, Jäger T, Di Fazio P, Jakab M, Wagner A, Neureiter D, Kiesslich T.

Int J Mol Sci. 2018 Oct 12;19(10). pii: E3128. doi: 10.3390/ijms19103128.

6.

Continuous, label-free, 96-well-based determination of cell migration using confluence measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Fuchs J, Pichler M, Ritter M, Jakab M, Helm K, Neureiter D, Kiesslich T.

Cell Adh Migr. 2019 Dec;13(1):76-82. doi: 10.1080/19336918.2018.1526612. Epub 2018 Oct 8.

PMID:
30295122
7.

Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.

Primavesi F, Klieser E, Cardini B, Marsoner K, Fröschl U, Thalhammer S, Fischer I, Hauer A, Urbas R, Kiesslich T, Neureiter D, Zitt M, Klug R, Wundsam H, Sellner F, Karner J, Függer R, Cakar-Beck F, Kornprat P, Öfner D, Stättner S; ASSO pNEN Study Group.

Eur J Surg Oncol. 2019 Feb;45(2):198-206. doi: 10.1016/j.ejso.2018.08.016. Epub 2018 Sep 3.

PMID:
30262324
8.

HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors.

Klieser E, Urbas R, Swierczynski S, Stättner S, Primavesi F, Jäger T, Mayr C, Kiesslich T, Fazio PD, Helm K, Neureiter D.

Int J Mol Sci. 2018 Sep 15;19(9). pii: E2781. doi: 10.3390/ijms19092781.

9.

The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Jäger T, Neureiter D, Fallaha M, Schredl P, Kiesslich T, Urbas R, Klieser E, Holzinger J, Sedlmayer F, Emmanuel K, Dinnewitzer A.

Strahlenther Onkol. 2018 Nov;194(11):991-1006. doi: 10.1007/s00066-018-1340-0. Epub 2018 Aug 1.

10.

Endoscopic submucosal dissection (ESD) for anal high-grade intraepithelial neoplasia: a case report.

Wagner A, Neureiter D, Holzinger J, Kiesslich T, Klieser E, Berr F.

Z Gastroenterol. 2018 May;56(5):495-498. doi: 10.1055/a-0578-9059. Epub 2018 May 7.

PMID:
29734448
11.

Miniaturization of the Clonogenic Assay Using Confluence Measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Pichler M, Ritter M, Jakab M, Neureiter D, Kiesslich T.

Int J Mol Sci. 2018 Mar 3;19(3). pii: E724. doi: 10.3390/ijms19030724.

12.

Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model.

Primavesi F, Swierczynski S, Klieser E, Kiesslich T, Jäger T, Urbas R, Hutter J, Neureiter D, Öfner D, Stättner S.

Oncol Lett. 2018 Mar;15(3):2913-2920. doi: 10.3892/ol.2017.7634. Epub 2017 Dec 18.

13.

Single-center implementation of endoscopic submucosal dissection (ESD) in the colorectum: Low recurrence rate after intention-to-treat ESD.

Wagner A, Neureiter D, Kiesslich T, Wolkersdörfer GW, Pleininger T, Mayr C, Dienhart C, Yahagi N, Oyama T, Berr F.

Dig Endosc. 2018 May;30(3):354-363. doi: 10.1111/den.12995. Epub 2018 Jan 3.

PMID:
29218732
14.

IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.

Kessler SM, Lederer E, Laggai S, Golob-Schwarzl N, Hosseini K, Petzold J, Schweiger C, Reihs R, Keil M, Hoffmann J, Mayr C, Kiesslich T, Pichler M, Kim KS, Rhee H, Park YN, Lax S, Obrist P, Kiemer AK, Haybaeck J.

Oncotarget. 2017 Sep 21;8(52):89736-89745. doi: 10.18632/oncotarget.21116. eCollection 2017 Oct 27.

15.

Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer.

Neureiter D, Kiesslich T, Ritter M, Mayr C.

Expert Opin Ther Targets. 2018 Jan;22(1):1-3. doi: 10.1080/14728222.2018.1406923. Epub 2017 Nov 20. No abstract available.

PMID:
29148857
16.

The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.

Mayr C, Helm K, Jakab M, Ritter M, Shrestha R, Makaju R, Wagner A, Pichler M, Beyreis M, Staettner S, Jaeger T, Klieser E, Kiesslich T, Neureiter D.

Hum Pathol. 2018 Feb;72:117-126. doi: 10.1016/j.humpath.2017.11.003. Epub 2017 Nov 11.

PMID:
29133140
17.

SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types.

Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, Schauer S, Kiesslich T, Kornprat P, Winder T, Eisner F, Gerger A, Stoeger H, Stauber R, Lackner C, Pichler M.

PLoS One. 2017 Nov 9;12(11):e0187814. doi: 10.1371/journal.pone.0187814. eCollection 2017.

18.

The H+/K+ ATPase Inhibitor SCH-28080 Inhibits Insulin Secretion and Induces Cell Death in INS-1E Rat Insulinoma Cells.

Jakab M, Ketterl N, Fürst J, Beyreis M, Kittl M, Kiesslich T, Hauser-Kronberger C, Gaisberger M, Ritter M.

Cell Physiol Biochem. 2017;43(3):1037-1051. doi: 10.1159/000481701. Epub 2017 Oct 2.

19.

Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancers-reply.

Neureiter D, Kiesslich T.

Hum Pathol. 2018 Jan;71:167-168. doi: 10.1016/j.humpath.2017.07.016. Epub 2017 Sep 2. No abstract available.

PMID:
28873357
20.

Biliary tract cancer stem cells - translational options and challenges.

Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T.

World J Gastroenterol. 2017 Apr 14;23(14):2470-2482. doi: 10.3748/wjg.v23.i14.2470. Review.

Supplemental Content

Loading ...
Support Center